Predictive Value of Pretreatment Haematological Markers in Cervical Cancer at a Third Level Health Institution

Justina Omoikhefe Alegbeleye *

University of Port Harcourt Teaching Hospital, Rivers State, Nigeria.

Merry Alali Jaja

Department of Obstetrics and Gynaecology, University of Port Harcourt Teaching Hospital, Rivers State, Nigeria.

*Author to whom correspondence should be addressed.


Abstract

Background: Inflammatory biomarker measurement is a low-cost method of identifying patients with advanced disease, and the risk of recurrence after treatment.

Objectives: To investigate if the pretreatment neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) can be used in predicting the stage of cervical cancer.

Materials and Methods: A cross-sectional analysis of seventy-eight women newly diagnosed with cervical cancer managed at the University of Port Harcourt Teaching Hospital between January 1, 2019, and December 31, 2022. A data collection form was used to collect socio-demographic and clinical characteristics from the patients after informed consent was obtained. Blood samples were collected and used to determine the pretreatment levels of NLR and PLR. The Receiver Operating Characteristic (ROC) curve was used to assess the predictive accuracy of the different haematological parameters for late-stage cervical cancer.

Results: PLR was significantly higher in advanced-stage cancer (p = 0.041). There was no statistically significant strong positive correlation between NLR (r = 0.195) and PLR (0.078) with cervical cancer staging (p > 0.05). None of the haematological parameters could be used as predictive markers for advanced-stage cervical cancer.

Conclusion: Pretreatment NLR and PLR did not predict the stage of cervical cancer in this study.

Keywords: Cervical cancer, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, predictive value, Port Harcourt


How to Cite

Alegbeleye, Justina Omoikhefe, and Merry Alali Jaja. 2023. “Predictive Value of Pretreatment Haematological Markers in Cervical Cancer at a Third Level Health Institution”. International Journal of Research and Reports in Gynaecology 6 (1):71-78. https://journalijrrgy.com/index.php/IJRRGY/article/view/87.


References

Ergen S, Barlas C, Dagdelen M, Can G, Sahinler I. The prognostic role of the pretreatment peripheral neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) in patients with cervical cancer. Ann Med Res 2021;28 (4):778-785.

Koulis TA, Kornaga EN, Banerjee R, Phan T, Ghatage P, Magliocco AM, et al. Anemia, leukocytosis, and thrombocytosis as prognostic factors in patients with cervical cancer treated with radical chemoradiotherapy: A retrospective cohort study. Clin Transl Radiat Oncol 2017;4: 51-56.

Jia W, Yuan L, Ni H, Xu B, Zhao P. Prognostic Value of Platelet-to-Lymphocyte Ratio, Neutrophil-to-Lymphocyte Ratio, and Lymphocyte-to-White Blood Cell Ratio in Colorectal Cancer Patients Who Received Neoadjuvant Chemotherapy. Technol Cancer Res Treat. 2021;20: 15330338211034291.

Gavrilescu MM, Hutanu I, Ioanid N, Musina, AM, Mihaela BA, Moscalu M, et al. Clinical Value of Hematological Biomarkers in Uterine Cervical Cancer. Chr. 2016;111 (6):493-499.

Palaia I, Tomao F, Di Pinto A, Pernazza A, Santangelo G, D'Alessandris N, et al. Response to Neoadjuvant Chemotherapy in Locally Advanced Cervical Cancer: The Role of Immune-related Factors. In Vivo 2021;35(2):1277–1283.

Adejumo R. 339 Ovarian cancer epidemiology in Jigawa, Nigeria. A 4-year review. Int J Gynecol Cancer 2020;

DOI: 10.1136/ijgc-2020-IGCS.291.

George S, Omotoso A, Pinto A, Mustapha A, Sanchez-Covarrubias AP, Umar UA, et al. An Assessment of Ovarian Cancer Histotypes Across the African Diaspora. Front Oncol 2021;11, DOI:10.3389/fonc.2021.732443.

Kim YW, Choi EH, Kim BR, Ko WA, Do YM, Kim IY. The impact of delayed commencement of adjuvant chemotherapy (eight or more weeks) on survival in stage II and III colon cancer: a national population-based cohort study. Oncotarget. 2017;10;8(45):80061-80072.

Balkwill F, Mantovani A. Inflammation, and cancer: back to Virchow? Lancet. 2001;357(9255):539-545.

Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 2010;140(6):883-899.

Templeton AJ, McNamara MG, Šeruga B, Vera-Badillo FE, Aneja P, Ocaña A, et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst 2014;106(6):dju124. DOI: 10.1093/jnci/dju124

Zhou X, Du Y, Huang Z, Xu J, Qiu T, Wang J, et al. Prognostic value of PLR in Various Cancers: A Meta-Analysis. PLoS One. 2014;9:e101119.

Kose M, Celik F, Kose SK, Arioz DT, Yilmazer M. Could the Platelet-to-Lymphocyte Ratio be a Novel Marker for Predicting Invasiveness of Cervical Pathologies? Asian Pac J Cancer Prev 2015;16(3):923-926.

Yildirim MA, Seckin KD, Togrul C, Baser E, Karsli MF, Gungor T, et al. Roles of Neutrophil/ Lymphocyte and Platelet/Lymphocyte Ratios in the Early Diagnosis of Malignant Ovarian Masses. Asian Pac J Cancer Prev. 2014;15 (16):6881-6885.

Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-674.

Roxburgh CS, Salmond JM, Horgan PG, Oien KA, McMillan DC. Comparison of the prognostic value of inflammation-based pathologic and biochemical criteria in patients undergoing potentially curative resection for colorectal cancer. Ann Surg. 2009;249(5):788-793.

Lee S, Oh SY, Kim SH, Lee JH, Kim MC, Kim KH, et al. Prognostic significance of neutrophil lymphocyte ratio and platelet lymphocyte ratio in advanced gastric cancer patients treated with FOLFOX chemotherapy. BMC Cancer 2013; 13: 350.

Guthrie GJ, Charles KA, Roxburgh CS, Horgan PG, McMillan DC, Clarke SJ. The systemic inflammation-based neutrophil-lymphocyte ratio: experience in patients with cancer. Crit Rev Oncol Hematol. 2013; 88(1):218-230.

Kwon HC, Kim SH, Oh SY, Lee S, Lee JH, Choi HJ, et al. Clinical significance of preoperative neutrophil-lymphocyte versus platelet-lymphocyte ratio in patients with operable colorectal cancer. Biomarkers. 2012;17(3):216-222.

Hong X, Cui B, Wang M, Yang Z, Wang L, Xu Q. Systemic immune-inflammation index, based on platelet counts and neutrophil-lymphocyte ratio, is useful for predicting prognosis in small cell lung cancer. Tohoku J Exp Med 2015;236(4) ;297-304.

Gunaldi M, Goksu S, Erdem D, Gunduz S, Okuturlar Y, Tiken E, et al. Prognostic impact of platelet/lymphocyte and neutrophil/lymphocyte ratios in patients with gastric cancer: a multicenter study. Int J Clin Exp Med 2015;8(4):5937-5942.

Lee YY, Choi CH, Kim HJ, Kim T J, Lee JW, Lee JH, et al. Pretreatment neutrophil: lymphocyte ratio as a prognostic factor in cervical carcinoma. Anticancer Res. 2012;32(4):1555-1561.

Zhang Y, Wang L, Liu Y, Wang S, Shang P, Gao Y, et al. Preoperative neutrophil-lymphocyte ratio before platelet-lymphocyte ratio predicts clinical outcome in patients with cervical cancer treated with initial radical surgery. Int J Gynecol Cancer 2014;24(7):1319-1325.

Nakamura K, Nishida T, Haruma T, Haraga J, Omichi C, Ogawa C, et al. Pretreatment platelet-lymphocyte ratio is an independent predictor of cervical cancer recurrence following concurrent chemoradiation therapy. Mol Cli Oncol. 2015;3(5):1001-1006.

Mizunuma M, Yokoyama Y, Futagami M, Aoki M, Takai Y, Mizunuma H. The pretreatment neutrophil-to-lymphocyte ratio predicts therapeutic response to radiation therapy and concurrent chemoradiation therapy in uterine cervical cancer. Int J Clin Oncol. 2015;20(5):989-996.

Wu J, Chen M, Liang C, Su W. Prognostic value of the pretreatment neutrophil-to-lymphocyte ratio in cervical cancer: a meta-analysis and systematic review. Oncotarget. 2017;8(8):13400-13412.

Nuchpramool P, Hanprasertpong J. Preoperative Neutrophil-Lymphocyte Ratio and Platelet-Lymphocyte Ratio Are Not Clinically Useful in Predicting Prognosis in Early-Stage Cervical Cancer. Surg Res Pract. 2018;2018:9162921.

Prabawa IPY, Bhargah A, Liwang F, Tandio DA, Tandio AL, Lestari AAW, et al. Pretreatment Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte Ratio (PLR) as a Predictive Value of Hematological Markers in Cervical Cancer. Asian Pac J Cancer Prev. 2019;20(3):863-868.

Lee HJ, Kim JM, Chin YJ, Chong GO, Park SH, Lee YH, et.al. Prognostic Value of Hematological Parameters in Locally Advanced Cervical Cancer Patients Treated with Concurrent Chemoradiotherapy. Anticancer Res. 2020; 40(1):451-458.

Han X, Liu S, Hosseinifard H, Imani S, Yang G, Yang L, et al. Descriptive statistics of dataset from the meta-analysis and meta-regression analysis on prognostic significance of pre-treatment systemic hemato-immunological indices of cervical cancer patients. Data in Brief. 2021;35:106925.

Long Y, Zhang Y, Ni L, Yuan X, Liu Y, Tao J, et al. Prognostic value of platelet- to-lymphocyte ratio in neoadjuvant chemotherapy for solid tumors: A PRISMA-compliant meta-analysis. Medicine. 2021; 100(29):e26202.

Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454 (7203):436-444.

Valle-Mendiola A, Gutiérrez-Hoya A, Lagunas-Cruz MDC, Weiss-Steider B, Soto-Cruz I. Pleiotropic Effects of IL-2 on Cancer: Its Role in Cervical Cancer. Mediators Inflamm. 2016;2849523.

Sabrkhany S, Griffioen AW, oude Egbrink MG. The role of blood platelets in tumor angiogenesis. Biochim Biophys Acta. 2011; 1815(2):189-196.

Nakamura K, Nakayama K, Tatsumi N, Minamoto T, Ishibashi T, Ohnishi K, et al. Prognostic significance of pre-treatment neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios in non-surgically treated uterine cervical carcinoma. Mol Clin Oncol. 2018;9(2):138-144.

Chun S, Shin K, Kim KH, Kim HY, Eo W, Lee JY, et al. The neutrophil-lymphocyte ratio predicts recurrence of cervical intraepithelial neoplasia. J Cancer. 2017; 8(12):2205-2211.

Sun P, Zhang F, Chen C, Bi X, Yang H, An X, et al. The ratio of hemoglobin to red cell distribution width as a novel prognostic parameter in esophageal squamous cell carcinoma: a retrospective study from southern China. Oncotarget 2016; 7 (27): 42650-42660.

Chen L, Zhang F, Sheng X-G, Zhang SQ, Chen YT, Liu BW, et al. Peripheral platelet/ lymphocyte ratio predicts lymph node metastasis and acts as a superior prognostic factor for cervical cancer when combined with neutrophil: Lymphocyte. Medicine. 2016;95(32):e4381.

Zhang X, Wang Y, Zhao L, Sang S, Zhang L. Prognostic value of platelet-to-lymphocyte ratio in oncologic outcomes of esophageal cancer: A systematic review and meta-analysis. Int J Biol Markers. 2018;1724600818766889.

Wu J, Chen M, Liang C, Su W. Prognostic value of the pretreatment neutrophil-to-lymphocyte ratio in cervical cancer: a meta-analysis and systematic review. Oncotarget. 2017;8(8):13400-13412.